Proceedings of the 38th Annual Meeting of Korean Society of Gynecologic Oncology 2023
DOI: 10.3802/jgo.2023.34.s1.tip07
|View full text |Cite
|
Sign up to set email alerts
|

A phase 2, double-blind, placebo-controlled, multicenter clinical trial comparing chemoimmunotherapy (paclitaxel-carboplatin-oregovomab [PCO]) versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as neoadjuvant therapy in patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma: FLORA-6 study

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles